If there is something that has always fascinated us, it is Fumagillin. Since time immemorial, Fumagillin has been an object of study, admiration and debate. Whether for its impact on history, its influence on culture, or its relevance in today's society, Fumagillin continues to be a topic of great interest to academics, professionals, and the curious alike. In this article, we will thoroughly explore all aspects related to Fumagillin, from its origins to its impact on the modern world. Through a thorough and enriching analysis, we hope to expand our knowledge and understanding of Fumagillin, and perhaps even discover new facets that surprise us. Join us on this fascinating journey through Fumagillin, and together we will unravel its mysteries and meanings. Do not miss it!
There are reports that fumagillin controls Nosema ceranae, which has recently been hypothesized as a possible cause of colony collapse disorder.
The latest report, however, has shown it to be ineffective against N. ceranae.
Fumagillin is also investigated as an inhibitor of malaria parasite growth.
Fumagillin can block blood vessel formation by binding to an enzyme methionine aminopeptidase 2 and for this reason, the compound, together with semisynthetic derivatives, are investigated as an angiogenesis inhibitor in the treatment of cancer.
The company Zafgen conducted clinical trials using the fumagillin analogbeloranib for weight loss, but they were unsuccessful.
Fumagillin is toxic to erythrocytesin vitro at concentrations greater than 10 μM.
Total synthesis
Fumagillin and the related fumagillol (the hydrolysis product) have been a target in total synthesis, with several reported successful strategies, racemic, asymmetric, and formal.
References
^F. R. Hanson, T. E. Elbe, J. Bacteriol. 1949, 58, 527
^Williams GR, Sampson MA, Shutler D, Rogers RE (November 2008). "Does fumagillin control the recently detected invasive parasite Nosema ceranae in western honey bees (Apis mellifera)?". Journal of Invertebrate Pathology. 99 (3): 342–344. doi:10.1016/j.jip.2008.04.005. PMID18550078.
^Lefkove B, Govindarajan B, Arbiser JL (August 2007). "Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors". Expert Review of Anti-Infective Therapy. 5 (4): 573–579. doi:10.1586/14787210.5.4.573. PMID17678422. S2CID41794515.
^
Gilbert MA, Granath WO (August 2003). "Whirling disease of salmonid fish: life cycle, biology, and disease". The Journal of Parasitology. 89 (4): 658–667. doi:10.1645/GE-82R. PMID14533670. S2CID8950955.
^Corey EJ, Snider BB (April 1972). "A total synthesis of (+-)-fumagillin". Journal of the American Chemical Society. 94 (7): 2549–2550. doi:10.1021/ja00762a080. PMID5016935.
^Kim D, Ahn SK, Bae H, Choi WJ, Kim HS (1997). "An asymmetric total synthesis of (−)-fumagillol". Tetrahedron Letters. 38 (25): 4437–4440. doi:10.1016/S0040-4039(97)00925-8.
^Hutchings M, Moffat D, Simpkins NS (2001). "A Concise Synthesis of Fumagillol". Synlett. 2001 (5): 0661–0663. doi:10.1055/s-2001-13359. S2CID196782462.
^Taber DF, Christos TE, Rheingold AL, Guzei IA (1999). "Synthesis of (−)-Fumagillin". Journal of the American Chemical Society. 121 (23): 5589. doi:10.1021/ja990784k. S2CID95897985.
^Boiteau JG, Van de Weghe P, Eustache J (August 2001). "A new, ring closing metathesis-based synthesis of (-)-fumagillol". Organic Letters. 3 (17): 2737–2740. doi:10.1021/ol016343z. PMID11506622.
^Bedel O, Haudrechy A, Langlois Y (2004). "A Stereoselective Formal Synthesis of (−)-Fumagillol". European Journal of Organic Chemistry. 2004 (18): 3813. doi:10.1002/ejoc.200400262.
^Yamaguchi J, Toyoshima M, Shoji M, Kakeya H, Osada H, Hayashi Y (January 2006). "Concise enantio- and diastereoselective total syntheses of fumagillol, RK-805, FR65814, ovalicin, and 5-demethylovalicin". Angewandte Chemie. 45 (5): 789–793. doi:10.1002/anie.200502826. PMID16365904.